Envisagenics is a technology company.
Envisagenics has raised $22.0M across 3 funding rounds.
Envisagenics has raised $22.0M in total across 3 funding rounds.
Envisagenics has raised $22.0M in total across 3 funding rounds.
Envisagenics's investors include 01 Advisors, AVANT BIO, Celesta, Company Capital, Conviction Partners, Crosscut Ventures, Garden City Companies, Madrona Ventures, Meritech Capital Partners, Operator Collective, Softbank Group, Village Global.
# High-Level Overview
Envisagenics is an AI-driven biotechnology company that develops drug discovery platforms focused on RNA splicing therapeutics.[1][2] The company builds SpliceCore®, a cloud-based machine learning platform that identifies novel drug targets by analyzing RNA sequencing data to uncover disease-causing splicing events.[2][3] It serves biopharmaceutical companies and researchers developing treatments for oncology, neurodegenerative diseases, and genetic disorders—conditions where traditional drug discovery methods have missed critical therapeutic opportunities.[2][4]
The core problem Envisagenics solves is the inefficiency of conventional gene-centric drug discovery approaches. SpliceCore is up to 250 times more likely to discover novel targets than traditional methods by taking an exon-centric approach combined with machine learning algorithms.[2][4] The company demonstrates strong growth momentum through strategic partnerships: it announced a multi-year research collaboration with Bristol Myers Squibb in November 2022 to identify splicing-derived oncology targets, and has secured Series A financing to scale operations.[2][5]
# Origin Story
Envisagenics emerged from Cold Spring Harbor Laboratory (CSHL), one of the world's leading biomedical research institutions.[6] The company is a spinout from the laboratory of Dr. Adrian R. Krainer, a pioneering expert in RNA splicing whose foundational work included the first in-vitro splicing studies and discovery of splicing's role in cancer and genetic diseases.[6] This scientific pedigree directly informed the company's founding in 2014 and its focus on splicing-based therapeutics.[1]
The company is led by Dr. Maria Luisa Pineda (Co-founder and CEO) and Dr. Martin Akerman (Co-founder and CTO), positioning it as a minority and woman-led biotech firm.[2][4] The Krainer laboratory's earlier success—including contributing to the FDA approval of Spinraza for Spinal Muscular Atrophy—validated the therapeutic potential of RNA-targeted approaches and provided the scientific foundation for Envisagenics' platform development.[6] The company has demonstrated early traction through academic partnerships, proof-of-concept studies, and successful fundraising rounds.[6]
# Core Differentiators
# Role in the Broader Tech Landscape
Envisagenics operates at the intersection of AI-driven drug discovery and precision medicine, two of biotech's most transformative trends. The company was recognized as an "Outperformer" among 15 leading AI drug target identification platforms, competing alongside technology giants like Google and NVIDIA.[1] This positioning reflects the broader shift toward computational approaches in early-stage drug development, where machine learning can dramatically reduce time and cost.
The timing is critical: pharmaceutical companies face mounting pressure to improve R&D productivity while AI/ML capabilities have matured sufficiently to extract actionable insights from complex biological data.[2][5] Envisagenics' focus on RNA splicing—a previously underexploited therapeutic avenue—addresses a genuine gap in the drug discovery ecosystem. By enabling biopharmaceutical partners to identify targets missed by conventional methods, the company influences how the entire industry approaches target validation and precision medicine strategies.
# Quick Take & Future Outlook
Envisagenics is positioned to become a foundational infrastructure player in AI-enabled drug discovery, particularly as RNA therapeutics gain regulatory and commercial momentum. The company's next phase will likely involve expanding its pharma partnership portfolio, demonstrating clinical validation of SpliceCore-derived targets, and potentially moving toward direct therapeutic development.
Key trends shaping its trajectory include accelerating adoption of AI in biopharma R&D, growing investment in RNA-based therapies, and increasing demand for precision medicine approaches that stratify patient populations. As more splicing-derived targets advance through clinical development, Envisagenics' platform becomes increasingly valuable—creating a virtuous cycle where successful partnerships drive platform validation, attracting larger collaborations.
The company's challenge will be translating platform success into tangible clinical outcomes. However, its scientific pedigree, strategic partnerships, and demonstrated ability to identify novel targets position it well to influence how the next generation of therapeutics are discovered.
Envisagenics has raised $22.0M across 3 funding rounds. Most recently, it raised $19.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $19.0M Series A | 01 Advisors, AVANT BIO, Celesta, Company Capital, Conviction Partners, Crosscut Ventures, Garden City Companies, Madrona Ventures, Meritech Capital Partners, Operator Collective, Softbank Group, Village Global, Jason Robins, Josh Silverman | |
| Apr 1, 2018 | $1.0M Seed | 01 Advisors, Celesta, Company Capital, Conviction Partners, Crosscut Ventures, Garden City Companies, Madrona Ventures, Meritech Capital Partners, Operator Collective, Softbank Group, Village Global, Jason Robins, Josh Silverman | |
| Nov 1, 2017 | $2.0M Seed | AVANT BIO |